Aproximación para establecer y evaluar la relevancia clínica de las interacciones medicamentosas en el tratamiento de pacientes infectados con virus de hepatitis C, revisión estructurada (actualización 2015 – 2017)

Autores/as

  • Daniel Esteban Pino Marín Universidad de Antioquia
  • Pedro Amariles Universidad de Antioquia
  • Jaime Alberto Peláez Alvárez Hospital infantil los Angeles
  • Gloria Priscilla Alvárez Osorio
  • Juliana González Ceballos

DOI:

https://doi.org/10.22516/25007440.252

Palabras clave:

Interacciones medicamentosas, Hepatitis C, Antivirales

Resumen

Objetivo: establecer y evaluar la relevancia clínica de las interacciones medicamentosas en el tratamiento de pacientes con hepatitis C.

Método: se realizó una búsqueda en PubMed/MedLine de artículos publicados en inglés y en español, desde el 1 de enero de 2015 hasta el 30 de marzo de 2017, utilizando los términos Mesh: Hepatitis C AND drug interactions OR herb-drug interactions OR food-drug interactions, de estudios realizados en humanos. La relevancia clínica de las interacciones medicamentosas se estableció y evaluó con base en la probabilidad de ocurrencia y la gravedad de la interacción.

Resultados: se identificaron 184 artículos, de los cuales 92 se seleccionaron por el título y resumen para revisión completa, a 2 de ellos no fue posible acceder al texto completo. De estos, 57 aportaban interacciones, lo que permitió identificar 155 parejas de interacciones medicamentosas, de las cuales 154 (99,4 %) fueron farmacocinéticas y 1 (0,6 %) farmacodinámica. Por su parte, de las 155 parejas, 34 (21,9 %) se valoraron de nivel 1; 73 (47,1 %) de nivel 2; 48 (31,0 %) de nivel 3; y 0 (0,0 %) de nivel 4. Además, se identificaron 29 parejas agrupadas como interacciones con evidencia de ausencia de relevancia clínica.

Conclusiones: más de 99 % de las interacciones medicamentosas de relevancia clínica son farmacocinéticas, asociadas con cambios en el metabolismo y el transporte de fármacos; el simeprevir y la terapia 3D (Paritaprevir/Ritonavir+ Ombitasvir+Dasabuvir) fueron los medicamentos con mayor número de interacciones.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Daniel Esteban Pino Marín, Universidad de Antioquia

Químico farmacéutico, depto de farmacia de la Universidad de Antioquia UdeA, Medellín. Grupo de promoción y prevención farmacéutica (P&PF) de la Universidad de Antioquia

Pedro Amariles, Universidad de Antioquia

Químico farmacéutico, depto de farmacia de la Universidad de Antioquia UdeA, Medellín. Grupo de promoción y prevención farmacéutica (P&PF) de la Universidad de Antioquia

Jaime Alberto Peláez Alvárez, Hospital infantil los Angeles

Químico farmacéutico, depto de farmacia de la Universidad de Antioquia UdeA, Medellín. Grupo de promoción y prevención farmacéutica (P&PF) de la Universidad de Antioquia

Gloria Priscilla Alvárez Osorio

Químico farmacéutico, depto de farmacia de la Universidad de Antioquia UdeA, Medellín. Grupo de promoción y prevención farmacéutica (P&PF) de la Universidad de Antioquia

Juliana González Ceballos

Químico farmacéutico, depto de farmacia de la Universidad de Antioquia UdeA, Medellín. Grupo de promoción y prevención farmacéutica (P&PF) de la Universidad de Antioquia

Referencias bibliográficas

Ministerio de Salud y Protección Social. Plan nacional de control de las hepatitis virales 2014-2017. Bogotá D. C.: MinSalud; 2014.

Boccaccio V, Bruno S. Optimal management of patients with chronic hepatitis C and comorbidities. Liver Int. 2015;35(Suppl 1):35-43. https://doi.org/10.1111/liv.12712.

Florian J, Mishra P, Arya V, Harrington P, Connelly S, Reynolds KS, et al. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. Clin Pharmacol Ther. 2015;98(4):394-402. https://doi.org/10.1002/cpt.185.

Gogela NA, Lin M V, Wisocky JL, Chung RT. Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep. 2015;12(1):68-78. https://doi.org/10.1007/s11904-014-0243-7.

Arends JE, Lieveld FI, Boeijen LL, de Kanter CTMM, van Erpecum KJ, Salmon D, et al. Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms? J Hepatol. 2015;63(5):1254-62. https://doi.org/10.1016/j.jhep.2015.06.034.

El Kassas M, Elbaz T, Hafez E, Esmat G. Safety of direct antiviral agents in the management of hepatitis C. Expert Opin Drug Saf. 2016;15(12):1643-52. https://doi.org/10.1080/14740338.2017.1240781.

Hill L. Hepatitis C virus direct-acting antiviral drug interactions and use in renal and hepatic impairment. Top Antivir Med. 2015;23(2):92-6.

Pino-Marín D, Giraldo N, Amariles P. Aproximación para establecer y evaluar la relevancia clínica de las interacciones medicamentosas en el tratamiento de pacientes infectados con virus de hepatitis C genotipo 1: Revisión estructurada TT - A Structured Review of Approaches for Establishing. Rev Colomb Gastroenterol. 2016;31(2):119-34. https://doi.org/10.22516/25007440.81.

Amariles P, Giraldo A, Faus MJ. Interacciones medicamentosas: aproximación para establecer y evaluar su relevancia clínica. 2007;129(1):27-35. https://doi.org/10.1157/13106681.

Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug Interactions with direct-acting antivirals for hepatitis C: Implications for HIV and transplant patients. Ann Pharmacother. 2015;49(6):674-87. https://doi.org/10.1177/1060028015576180.

Esposito I, Labarga P, Barreiro P, Fernandez-Montero J V, de Mendoza C, Benítez-Gutiérrez L, et al. Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects. Expert Opin Drug Saf. 2015;14(9):1421-34. https://doi.org/10.1517/14740338.2015.1073258.

Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opin Drug Metab Toxicol. 2016;12(7):721-31. https://doi.org/10.1080/17425255.2016.1183644.

Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, Beumont-Mauviel M, Simion A. Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir. Clin Pharmacokinet. 2016;55(2):197-208. https://doi.org/10.1007/s40262-015-0314-y.

Bonacci M, Lens S, Mariño Z, Forns X. Challenges in Special Populations: HIV/HCV Coinfection, Liver Transplantation and Patients with End-Stage Renal Disease. Dig Dis. 2016 May 11;34(4):317–26.

Coilly A, Roche B, Duclos-Vallée J-C, Samuel D. Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals. Liver Int. 2015;35 Suppl 1:44-50. https://doi.org/10.1111/liv.12728.

Del Bello D, Ita Nagy F, Hand J, Khedemi R, Lécluse-Barth J, Dieterich D, et al. Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS. 2015;10(5):337-47. https://doi.org/10.1097/COH.0000000000000182.

Ferenci P, Kozbial K, Mandorfer M, Hofer H. HCV targeting of patients with cirrhosis. J Hepatol. 2015;63(4):1015-22. https://doi.org/10.1016/j.jhep.2015.06.003.

Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Clin Pharmacokinet. 2015;54(7):677-90. https://doi.org/10.1007/s40262-015-0261-7.

Ueda Y, Uemoto S. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients. Transplantation. 2016;100(1):54-60. https://doi.org/10.1097/TP.0000000000000860.

Vespasiani-Gentilucci U, Galati G, Gallo P, De Vincentis A, Riva E, Picardi A. Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World J Gastroenterol. 2015;21(24):7412-26. https://doi.org/10.3748/wjg.v21.i24.7412.

Renet S, Chaumais M-C, Antonini T, Zhao A, Thomas L, Savoure A, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015;149(6):1378-80.e1. https://doi.org/10.1053/j.gastro.2015.07.051.

Sabo JP, Kort J, Ballow C, Kashuba ADM, Haschke M, Battegay M, et al. Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation. J Clin Pharmacol. 2015;55(4):467-77. https://doi.org/10.1002/jcph.436.

Boesecke C, Rockstroh JK. Treatment of chronic HCV genotype 1 coinfection. Curr HIV/AIDS Rep. 2015;12(3):326-35. https://doi.org/10.1007/s11904-015-0278-4.

Dick TB, Lindberg LS, Ramirez DD, Charlton MR. A clinician’s guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. Hepatology. 2016;63(2):634-43. https://doi.org/10.1002/hep.27920.

Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63(1):20-9. https://doi.org/10.1016/j.jhep.2015.01.026.

Eley T, Garimella T, Li W, Bertz RJ. Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions. Clin Pharmacokinet. 2015;54(12):1205-22. https://doi.org/10.1007/s40262-015-0299-6.

Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, et al. Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir. Antimicrob Agents Chemother. 2015;60(1):105-14. https://doi.org/10.1128/AAC.01778-15.

Badri PS, King JR, Polepally AR, McGovern BH, Dutta S, Menon RM. Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Clin Pharmacokinet. 2016;55(3):275-95. https://doi.org/10.1007/s40262-015-0317-8.

Smith MA, Lim A. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther. 2015;9:6083-94. https://doi.org/10.2147/DDDT.S80226.

Mogalian E, German P, Kearney BP, Yang CY, Brainard D, McNally J, et al. Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir. Clin Pharmacokinet. 2016;55(5):605-13. https://doi.org/10.1007/s40262-015-0334-7.

Toussaint-Miller KA, Andres J. Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection. Ann Pharmacother. 2015;49(9):1015-30. https://doi.org/10.1177/1060028015592015.

Soriano V, Labarga P, de Mendoza C, Fernández-Montero J V, Esposito I, Benítez-Gutiérrez L, et al. New hepatitis C therapies for special patient populations. Expert Opin Pharmacother. 2016;17(2):217-29. https://doi.org/10.1517/14656566.2016.1112790.

Chen T-Y, Jain MK. Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens. AIDS Patient Care STDS. 2015;29(6):329-37. https://doi.org/10.1089/apc.2014.0247.

Wyles DL. Regimens for Patients Coinfected with Human Immunodeficiency Virus. Clin Liver Dis. 2015;19(4):689-706, vi-vii. https://doi.org/10.1016/j.cld.2015.06.008.

Childs K, Taylor C, Dieterich D, Agarwal K. Directly acting antivirals for hepatitis C virus arrive in HIV/hepatitis C virus co-infected patients: from “mind the gap” to “where”s the gap?’. AIDS. 2016;30(7):975-89. https://doi.org/10.1097/QAD.0000000000001042.

El-Sherif O, Back D. Drug interactions of hepatitis C direct-acting antivirals in the HIV-infected person. Curr HIV/AIDS Rep. 2015;12(3):336-43. https://doi.org/10.1007/s11904-015-0277-5.

El-Sherif O, Khoo S, Solas C. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection. Curr Opin HIV AIDS. 2015;10(5):348-54. https://doi.org/10.1097/COH.0000000000000185.

Rockstroh JK. Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals. Liver Int. 2015;35 Suppl 1:51-5. https://doi.org/10.1111/liv.12721.

Brennan BJ, Poirier A, Moreira S, Morcos PN, Goelzer P, Portmann R, et al. Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir. Clin Pharmacokinet. 2015;54(5):537-49. https://doi.org/10.1007/s40262-014-0222-6.

Khatri A, Dutta S, Wang H, Podsadecki T, Trinh R, Awni W, et al. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. Clin Infect Dis. 2016;62(8):972-9. https://doi.org/10.1093/cid/civ1213.

Patel N, Nasiri M, Koroglu A, Amin R, McGuey L, McNutt L-A, et al. Prevalence of Drug-Drug Interactions upon Addition of Simeprevir- or Sofosbuvir-Containing Treatment to Medication Profiles of Patients with HIV and Hepatitis C Coinfection. 2015;31(2). https://doi.org/10.1089/aid.2014.0215.

Scavone C, Sportiello L, Rafaniello C, Mascolo A, Sessa M, Rossi F, et al. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opin Drug Saf. 2016;15(sup2):85-100. https://doi.org/10.1080/14740338.2016.1221396.

Sebhatu P, Martin MT. Genotype 1 hepatitis C virus and the pharmacist’s role in treatment. Am J Health Syst Pharm. 2016;73(11):764-74. https://doi.org/10.2146/ajhp150704.

Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig. 2015;35(5):281-9. https://doi.org/10.1007/s40261-015-0279-5.

Audrey C, Raffaele B. Liver transplantation for hepatitis C virus in the era of direct-acting antiviral agents. Curr Opin HIV AIDS. 2015;10(5):361-8. https://doi.org/10.1097/COH.0000000000000186.

Badri P, Dutta S, Coakley E, Cohen D, Ding B, Podsadecki T, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant. 2015;15(5):1313-22. https://doi.org/10.1111/ajt.13111.

Cholongitas E, Pipili C, Papatheodoridis G. Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. World J Gastroenterol. 2015;21(32):9526-33. https://doi.org/10.3748/wjg.v21.i32.9526.

Coilly A, Roche B, Duclos-Vallée J-C, Samuel D. News and challenges in the treatment of hepatitis C in liver transplantation. Liver Int. 2016;36 Suppl 1:34-42. https://doi.org/10.1111/liv.13017.

Kawaoka T, Imamura M, Kan H, Fujino H, Fukuhara T, Kobayashi T, et al. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report. Transplant Proc. 2015;47(3):809-14. https://doi.org/10.1016/j.transproceed.2014.10.052.

Kwo PY, Badshah MB. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Curr Opin Organ Transplant. 2015;20(3):235-41. https://doi.org/10.1097/MOT.0000000000000198.

Perumpail RB, Wong RJ, Ha LD, Pham EA, Wang U, Luong H, et al. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis. 2015;17(2):275-8. https://doi.org/10.1111/tid.12348.

Zha J, Badri PS, Ding B, Uchiyama N, Alves K, Rodrigues-Jr L, et al. Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects. Clin Ther. 2015;37(11):2560-71. https://doi.org/10.1016/j.clinthera.2015.09.015.

Fazel Y, Lam B, Golabi P, Younossi Z. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Expert Opin Drug Saf. 2015;14(8):1317-26. https://doi.org/10.1517/14740338.2015.1053868.

Rosenthal ES, Kottilil S, Polis MA. Sofosbuvir and ledipasvir for HIV/HCV co-infected patients. Expert Opin Pharmacother. 2016;17(5):743-9. https://doi.org/10.1517/14656566.2016.1157580.

Joseph D, Rose P, Strelkowa N, Schultz A, Garcia J, Elgadi M, et al. Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2015;55(4):384-91. https://doi.org/10.1002/jcph.418.

Kardashian AA, Price JC. Hepatitis C virus-HIV-coinfected patients and liver transplantation. Curr Opin Organ Transplant. 2015;20(3):276-85. https://doi.org/10.1097/MOT.0000000000000199.

Rodriguez-Torres M, Gaggar A, Shen G, Kirby B, Svarovskaia E, Brainard D, et al. Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV. J Acquir Immune Defic Syndr. 2015;68(5):543-9. https://doi.org/10.1097/QAI.0000000000000516.

Vionnet J, Pascual M, Chtioui H, Giostra E, Majno PE, Decosterd LA, et al. Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report. BMC Gastroenterol. 2015;15(1):38. https://doi.org/10.1186/s12876-015-0259-5.

Meemken L, Hanhoff N, Tseng A, Christensen S, Gillessen A. Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy. Ann Pharmacother. 2015;49(7):796-807. https://doi.org/10.1177/1060028015581848.

Coilly A, Roche B, Duclos-Vallée J-C, Samuel D. Management of post transplant hepatitis C in the direct antiviral agents era. Hepatol Int. 2015;9(2):192-201. https://doi.org/10.1007/s12072-015-9621-5.

Das D, Pandya M. Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy. Mini Rev Med Chem. 2018;18(7):584-596. https://doi.org/10.2174/1389557517666170913111930.

Rey D, Muret P, Piroth L. Optimum combination therapy regimens for HIV/HCV infection. Expert Rev Anti Infect Ther. 2016;14(3):299-309. https://doi.org/10.1586/14787210.2016.1147952.

Soriano V, Labarga P, Barreiro P, Fernandez-Montero J V, de Mendoza C, Esposito I, et al. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol. 2015;11(3):333-41. https://doi.org/10.1517/17425255.2015.998997.

Dumond JB, Rigdon J, Mollan K, Tierney C, Kashuba ADM, Aweeka F, et al. Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results. J Acquir Immune Defic Syndr. 2015;70(5):510-4. https://doi.org/10.1097/QAI.0000000000000777.

Smolders EJ, Pape S, de Kanter CTMM, van den Berg AP, Drenth JPH, Burger DM. Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation? Int J Antimicrob Agents. 2017;49(3):379-82. https://doi.org/10.1016/j.ijantimicag.2016.12.004.

Publicado

2019-07-02

Cómo citar

Pino Marín, D. E., Amariles, P., Peláez Alvárez, J. A., Alvárez Osorio, G. P., & González Ceballos, J. (2019). Aproximación para establecer y evaluar la relevancia clínica de las interacciones medicamentosas en el tratamiento de pacientes infectados con virus de hepatitis C, revisión estructurada (actualización 2015 – 2017). Revista Colombiana De Gastroenterología, 34(2), 159–176. https://doi.org/10.22516/25007440.252

Número

Sección

Revisión de tema

Métricas

Crossref Cited-by logo
Estadísticas de artículo
Vistas de resúmenes
Vistas de PDF
Descargas de PDF
Vistas de HTML
Otras vistas
QR Code

Algunos artículos similares: